Back to Search
Start Over
Prodigiosin inhibits bacterial growth and virulence factors as a potential physiological response to interspecies competition.
- Source :
-
PloS one [PLoS One] 2021 Jun 23; Vol. 16 (6), pp. e0253445. Date of Electronic Publication: 2021 Jun 23 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Prodigiosin, a red linear tripyrrole pigment, has long been recognised for its antimicrobial property. However, the physiological contribution of prodigiosin to the survival of its producing hosts still remains undefined. Hence, the aim of this study was to investigate the biological role of prodigiosin from Serratia marcescens, particularly in microbial competition through its antimicrobial activity, towards the growth and secreted virulence factors of four clinical pathogenic bacteria (methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Salmonella enterica serovar Typhimurium and Pseudomonas aeruginosa) as well as Staphylococcus aureus and Escherichia coli. Prodigiosin was first extracted from S. marcescens and its purity confirmed by absorption spectrum, high performance liquid chromatography (HPLC) and liquid chromatography-tandem mass spectrophotometry (LC-MS/MS). The extracted prodigiosin was antagonistic towards all the tested bacteria. A disc-diffusion assay showed that prodigiosin is more selective towards Gram-positive bacteria and inhibited the growth of MRSA, S. aureus and E. faecalis and Gram-negative E. coli. A minimum inhibitory concentration of 10 μg/μL of prodigiosin was required to inhibit the growth of S. aureus, E. coli and E. faecalis whereas > 10 μg/μL was required to inhibit MRSA growth. We further assessed the effect of prodigiosin towards bacterial virulence factors such as haemolysin and production of protease as well as on biofilm formation. Prodigiosin did not inhibit haemolysis activity of clinically associated bacteria but was able to reduce protease activity for MRSA, E. coli and E. faecalis as well as decrease E. faecalis, Salmonella Typhimurium and E. coli biofilm formation. Results of this study show that in addition to its role in inhibiting bacterial growth, prodigiosin also inhibits the bacterial virulence factor protease production and biofilm formation, two strategies employed by bacteria in response to microbial competition. As clinical pathogens were more resistant to prodigiosin, we propose that prodigiosin is physiologically important for S. marcescens to compete against other bacteria in its natural soil and surface water environments.<br />Competing Interests: The authors have declared that no competing interests exist.
- Subjects :
- Biofilms growth & development
Enterococcus faecalis drug effects
Enterococcus faecalis growth & development
Methicillin-Resistant Staphylococcus aureus drug effects
Methicillin-Resistant Staphylococcus aureus growth & development
Pseudomonas aeruginosa drug effects
Pseudomonas aeruginosa growth & development
Salmonella typhi drug effects
Salmonella typhi growth & development
Anti-Bacterial Agents pharmacology
Biofilms drug effects
Prodigiosin pharmacology
Virulence Factors
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 16
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 34161391
- Full Text :
- https://doi.org/10.1371/journal.pone.0253445